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Abstract: We report the case of a rare hemoglobin variant, “Hemoglobin J”, discovered while 
performing hemoglobin electrophoresis following exchange transfusion of a sickle cell disease 
patient. It is usual practice in our institution to conﬁ  rm the hemoglobin S level in sickle cell disease 
patients after red cell exchange. The patient had received 5 red cell units and the source of this variant 
was traced back to two of those units. Due to the uncertain clinical impact of this variant, and the 
lack of speciﬁ  c guidelines, the two donors were deferred from future donations to our institution.
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Introduction
The clinical phenotype of sickle cell disease most commonly has one of the following 
genotypes: HbS/S, HbS/C or HbS/B thalassemia. Less commonly, the genotype may be 
double heterozygous traits of hemoglobin S with an uncommon hemoglobin trait such 
as Hb D, Hb O-Arab, or hemoglobin Lepore. The clinical impact of rare hemoglobin 
variants such as Hb J when combined with hemoglobin S disease (or trait) is not clear 
in the medical literature. Many sickle cell disease patients are on chronic transfusion 
to prevent stroke and other complications. Routine post-transfusion testing includes 
hemoglobin electrophoresis, mainly to assess the level of hemoglobin S. The goal is 
to maintain the patient hematocrit at 25% to 30% and the proportion of HbS below 
30% (Elghetany and Davy 2001; Brecher 2005).
Case report
A 44-year-old African American male with history of sickle cell anemia presented to 
our institution for scheduled red blood cell exchange transfusion. He received 5 units 
of red blood cells matched for C, E, and K red cell phenotype.
Pre and post transfusion hemoglobin electrophoresis was performed and results 
revealed a new band on the electrophoretic gel, indicating the patient had “acquired” 
a new hemoglobin variant.
The variant band was seen in the location of Hb J (a fast migrating variant) on 
isoelectric focusing (IEF) and cellulose acetate. It migrated with “A” on citrate agar. 
The variant constituted approximately 15% of total hemoglobin.
Clinical follow up of the patient showed no complications and the clinical course 
was consistent with the patient’s underlying medical condition.
Retained segments from the donated units were obtained and hemoglobin electro-
phoresis revealed two of the suspected units having hemoglobin J. Those units were 
donated by two sisters.
Pathologic ﬁ  ndings
The patient’s pre- and post-exchange hematological values are shown in Table 1. 
His pre- and post-transfusion hemoglobin electrophoresis was performed with the Therapeutics and Clinical Risk Management 2008:4(3) 650
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following results: Cellulose acetate with a prominent Hb A 
band, smaller band in the S region, and a fast hemoglobin 
in the position of Hb J (Figure1). The bands on citrate agar 
(acid) show prominent A and a smaller band located in the 
position of S (Figure 2). IEF was done on samples from 
the patient blood and the 5 donated units. The variant band 
appeared in three samples (the patient’s blood and two of the 
donated units), located in the position of Hb J (these bands 
were more prominent in the donor’s sample) (Figure 3).
The source of the variant band was apparently the 2 units of 
transfused blood. The donor center was notiﬁ  ed and the trans-
fused units were then traced to determined signiﬁ  cant donor 
history, such as possible recalls of any other components.
Discussion
The human hemoglobin molecule is composed of polypeptide 
chains called globins, and iron-containing porphyrin rings 
termed heme. Every hemoglobin variant is composed of 
two alpha and two nonalpha globin chains, while the heme 
component is usually the same.
Hemoglobinopathies are a group of inherited mutations 
of the globin genes leading to qualitative and/or quantitative 
abnormalities of globin synthesis.
There are hundreds of different variants of hemoglobin 
caused by structural alteration of alpha, beta, or gamma globin 
chains varying from amino acids replacements, elongated 
chains, deletions, insertions, or both deletions and insertions 
(Huisman et al 1998; Elghetany and Davy 2001).
Abnormalities of beta-chain or alpha-chain produce most 
of the clinically signiﬁ  cant hemoglobinopathies.
The status of zygosity also plays a very important role in 
the expression and detection of the disorder. In heterozygous 
variants the other normal allelic gene produces normal chains 
which may compensate for the defective gene. In the homo-
zygous state, both allelic genes are affected which results in 
the production of a large amount of the variant (Scrivener 
et al 1985; Elghetany and Davy 2001).
Table 1 Patient’s pre- and post-exchange CBC results
 Pre-transfusion  Post-transfusion  Reference  ranges
RBC  2.87  3.29  (3.9–5.3) M/cu mm
Hb 8.3  9.7  (11.5–13.5)  g/dL
Hct 24.4%  29.1%  (34%–40%)
RDW 23.9%  18.8%  (10%–14.1%)
Abbreviations: Hb, hemoglobin; Hct, hematocrit; RBC, red blood cell; RDW, red 
cell distribution width.
Figure 1 Post-red cell exchange hemoglobin electrophoresis (cellulose acetate, pH 
8.6) of the patient showing bands at the positions of Hb S, Hb A, and Hb J.
Abbreviation: Hb, hemoglobin.
C S F    A             J
Control
Patient
Cellulose acetate
Figure 2 Post-red cell exchange hemoglobin electrophoresis (citrate agar, pH 4.6) 
of the patient showing bands at positions Hb S and Hb A.
Abbreviation: Hb, hemoglobin.
Citrate agar (Acid)
CS A     F
Control
Patient
Figure 3 Hemoglobin electrophoresis (isoelectric focusing method) showing a band 
of Hb J (arrowhead) in the patient (post-exchange) and the two red cell units from 
the implicated donors.
Abbreviation: Hb, hemoglobin.
Isoelectric focusing
CS F A J N
Control
Donor 1
Donor 2
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Chicago (beta76(E20)Ala-Asp), Hb-J Sardegna (alpha50(CE8)
His-Asp), and Hb-J Toronto 9 alpha5(A3)Ala-Asp), etc. 
They all have an electrophoretic mobility “faster” than “A” 
on cellulose acetate (ie, close to the anode) in common. All 
are classiﬁ  ed under “variants of the alpha- or beta-chains” 
(single or multiple base changes), or ”hemoglobins with 
more than one amino acid substitution in the alpha chain” 
(eg, J-Singapore (alpha78(EF7)Asn-Asp) (Botha et al 1966; 
Lambridis et al 1986; stidda et al 2002).
One recently described hemoglobin J, found in a few 
members of an Italian family, named Hb J-Europa has a 
beta chain substitution (beta62(E6)Ala-Asp) (Huisman 
et al 1998).
Hemoglobin J (depending on its type) has different charac-
teristics and functions. For example hemoglobin J Capetown 
(α2 92Gln β2), the most commonly seen Hb J variant (CGG-
CAG), is associated in the heterozygous state with increased 
oxygen afﬁ  nity and polycythemia. Those affected may also 
have a mild erythrocytosis and microcytosis (Botha et al 1966; 
Elghetany and Davy 2001). Other variants like Hb J Sardegna 
will show a completely unremarkable clinical picture in the 
heterozygote. Hemoglobin J Bancock (beta 56 Gly-Asp) 
and J Baltimore (beta 16 Gly-Asp) have been described 
in combination with sickle hemoglobin. These individuals 
of African descent were reportedly clinically asymptomatic, 
however, as a double heterozygote there may be the potential 
of sickle cell trait-like complications (Gellady and Schwartz 
1973; Gunay et al 1974; Weatherall 1974).
In this particular case, review of the history of the two 
blood donors revealed them to be sisters with no signiﬁ  cant 
past medical history (which would have deferred them as 
donors initially). These sisters, 81- and 83-year-old Cauca-
sian women, from French, German, and English descent had 
a long history of blood donation (more than 15 donations 
each, starting in 1997). They were unaware of having this 
hemoglobin variant and were not aware of any abnormalities 
in their family (parents and 3 siblings).
There were no transfusion-associated adverse events 
reported in any of the recipients of their previously donated 
red blood cells, nor in the patient who received the current 
units. Further characterization of this hemoglobin variant 
was not indicated clinically, so molecular studies were not 
pursued.
The decision to defer the donors was made at the discre-
tion of the medical director of our blood donor center. This 
decision is admittedly open for questions and debate as there 
are currently no speciﬁ  c guidelines or policies in the medical 
literature for accepting or deferring donors after discovering 
Table 2 Patient’s pre- and post-transfusion hemoglobin electrophoresis 
tests
 Pre-transfusion  Post-transfusion
Hb-A 63.0%  71.5%
Hb-A2 3.5%  2.0%
Hb-S 33.5%  11.0%
Hb variant None  15.5%
Abbreviation: Hb, hemoglobin.
The vast majority of hemoglobin variants are encountered 
in the heterozygous state and most individuals carrying these 
variants have a completely normal physical picture and 
normal hematological tests. In the US, most hemoglobin 
variants are diagnosed in early childhood. This is mainly a 
beneﬁ  t of newborn screening which began in the 1980’s and 
is currently conducted in at least 44 states.
One of the most common hemoglobinopathies is sickle 
hemoglobin (Hb S), which is responsible for the sickle cell 
disease and trait. The molecular nature of this hemoglobin 
variant is a substitution of valine for glutamic acid at the sixth 
amino acid position in the beta globin gene, which results in 
decreased solubility of Hb, causing red cells to sickle (Suarez 
et al 1999; Elghetany and Davy 2001).
Most hemoglobinopathies are prevalent in tropical 
regions, perhaps due to the advantage of the heterozygote 
state in areas where malaria is endemic. Malaria parasites 
live inside red blood cells, but subtly disturb normal cel-
lular function. In patients predisposed to rapid clearance of 
red blood cells, this may lead to early destruction of cells 
infected with the parasite and increased chance of survival 
for the carrier of the trait.
The prevalence of Hb S in the US is mainly in people from 
African or Hispanic descent. Sickle trait has a prevalence of 
8%–10% among African Americans. Approximately 1/500 
African Americans and 1/1000 Hispanics have sickle cell 
anemia.
The prevalence of hemoglobin variants among blood 
donors is unknown, as no hemoglobin electrophoresis is 
routinely performed on donated units.
We are aware of only a few articles in the literature 
describing hemoglobin variants acquired through transfusion 
(Gibaud et al 1974; Rechavi et al 1986; Strobel et al 1987; 
Robertson et al 1997; Suarez et al 1999).
To our knowledge there is no reported case in the litera-
ture of transfusion-acquired hemoglobin J.
There are more than 50 hemoglobin J variants described 
in the literature. For example, Hb-J Capetown (alpha92(FG4) 
Arg-Gln), Hb-J Buda (alpha61(E10)Lys-Asn), Hb-J Therapeutics and Clinical Risk Management 2008:4(3) 652
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a rare hemoglobin variant. We hope that this case report will 
stimulate discussions that will lead to speciﬁ  c guidelines.
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